Biosimilar from Mycenax Completes Clinical Trials in Taiwan, South Korea
- Posted on 02 November 2009
Mycenax Biotech has announced that its rheumatoid arthritis and psoriasis drug TuNEX, a biosimilar version of etanercept, has successfully completed a Phase I trial in South Korea and Phase I/II clinical trials in Taiwan.
The company also announced that the drug would undergo a Phase III clinical trial soon, with plans to also undertake multinational, multicenter Phase III studies in several countries such as Korea and India, using the clinical data obtained to apply to market the drug in other locations globally.
